Dr Reddy is a dedicated physician-scientist deeply committed to advancing transformative cancer therapies for individuals facing limited time and options due to their diagnosis. Has extensive expertise in cancer therapeutics research and development, specifically in targeted therapies, immuno-oncology, and cell therapy. Spanning all stages of development from pre-IND to NDA/BLA. He has consistently contributed to groundbreaking advancements.

Dr Reddy has diverse experiences, from large pharmaceutical companies to small biopharmaceutical firms, as wells as pre- and post-IPO stage companies. Has successfully built and led large teams of physicians, scientists, and drug developers across different organizations. During his tenure as Chief Medical Officer at Autolus Ltd, he spearheaded the development of the CAR-T cell clinical program, introducing first-in-class targets. He also made pivotal contributions at Janssen Pharmaceuticals (Johnson & Johnson) and GlaxoSmithKline played a crucial role in obtaining marketing authorizations for innovative therapies such as Mekinist (Trametinib), Tafinlar (Dabrafenib), and Balversa (Erdafitinib).

In his most recent role as the Chief Research & Development Officer at Tmunity Therapeutics, a clinical biotherapeutics company, he led the creation of next generation engineered cell therapies for both solid and heme malignancies until the company’s acquisition by Kite/Gilead. Additionally, as the President and interim CEO, he successfully navigated complex challenges in a tough environment, managing all aspects of the company independently. Including overseeing R&D, manufacturing, the board, investors, founders, and external partners. While ensuring the efficient operation of the company, the clinical and research programs, as well as building and retaining a highly talented team. These accomplishments significantly increased value for investors and stakeholders, culminating in a successful series-C financing and a valuable acquisition deal with Kite/Gilead.

In addition to corporate roles, Dr Reddy served as an adjunct faculty member in thoracic medical oncology at the Hospital of the University of Pennsylvania. He has a Bachelor of Medicine and Bachelor of Surgery from Sri Venkateshwara Medical College, a Doctor of Medicine in biochemistry from All India Institute of Medical Sciences, a Residency in Internal Medicine at Albert Einstein Medical Center, Philadelphia, and a fellowship in Medical Oncology at the University of Texas M. D. Anderson Cancer Center.

Currently he serves as the founder and CEO of Quneus, a gene therapy company focused on simplifying cell and gene therapies. He also serves on the board of OligoImmune, an antisense oligo company that he co-founded and advises several stealth and early-stage companies.